×
Choose Speciality

EXPLORE!

LOGIN

By signing up or signing in to eMediNexus, you consent to eMediNexus collecting and using your personal data in accordance with our Privacy Policy. We are committed to safeguarding your information and ensuring the highest standards of data protection. Your trust and privacy are of utmost importance to us.

Inhaled long-acting bronchodilators increase heart disease risk in COPD patients

  1112 Views

eMediNexus    03 January 2018

New use of inhaled long-acting bronchodilators (long-acting β2-agonists [LABAs] or long-acting antimuscarinic antagonists [LAMAs]) in patients with chronic obstructive pulmonary disease (COPD) is associated with 1.5-fold increase in the risk of cardiovascular disease (CVD) within a month of starting treatment. These findings from an observational study were published online January 2, 2018 in JAMA Internal Medicine.

To comment on this article,
create a free account.

Sign Up to instantly get access to 10000+ Articles & 1000+ Cases

Already registered?

Login Now

Most Popular Articles

News and Updates

eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.